[Antiretroviral prophylaxis after non-occupational exposure to HIV in Abidjan (Cote d'Ivoire)]

Med Mal Infect. 2010 Oct;40(10):574-81. doi: 10.1016/j.medmal.2010.04.008.
[Article in French]

Abstract

Objective: The aim of this study was to assess the tolerability and adherence to all non-occupational post-exposure prophylaxis (PEP) for cases of HIV exposure in Abidjan.

Method: We retrospectively studied all post-exposure prophylaxis for non-occupational exposures to HIV prescribed from January 1st, 2000 to December 31st, 2007 in the Abidjan infectious diseases department. We analyzed the types of exposure, socio-demographic characteristics of patients, antiretroviral therapy regimens, adherence and tolerability, duration of the treatment, and post-exposure follow-up.

Results: Over these eight years, we managed 128 consultations for non-professional exposures to HIV (50 male [39%], 78 female patients [61%]), average age 24.8 years (four-54 years). The most frequent exposures were due to rape (n=74), condom rupture (n=29), and occasional unprotected sex (n=21). The average delay before consultation was 20.8 hours. The antiretroviral chemoprophylaxis included a protease inhibitor in 93% of the cases; 80.5% of patients completed 28 days of chemoprophylaxis, while 8.6% interrupted the treatment, and 10.9% were lost to follow-up. The most frequent adverse effects were gastrointestinal, reported by 79 patients (61.7%). Only 34 patients (26.6%) returned for clinical and biological post-exposure follow-up with HIV control at third month, without documented seroconversion.

Conclusion: Cases of sexual exposure to HIV are the main indication for post-exposure prophylaxis in Abidjan, except for occupational exposure to blood. However, post-exposure prophylaxis should be available in the units of primary care, such as emergencies departments.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Bites, Human
  • Child
  • Child, Preschool
  • Condoms
  • Cote d'Ivoire
  • Equipment Failure
  • Female
  • Gastrointestinal Diseases / chemically induced
  • HIV Infections / prevention & control*
  • HIV Infections / transmission
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use
  • HIV Seropositivity
  • Humans
  • Male
  • Middle Aged
  • Needlestick Injuries
  • Patient Compliance
  • Post-Exposure Prophylaxis* / statistics & numerical data
  • Rape
  • Retrospective Studies
  • Treatment Outcome
  • Unsafe Sex
  • Young Adult

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors